Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
Acquired by Uro Gen Pharma in 2019
|
| gptkbp:focus |
Urology
|
| gptkbp:founded_in |
gptkb:2010
|
| gptkbp:founder |
gptkb:David_A._Kessler
|
| gptkbp:headquarters |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Taris Biomedical
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:mission |
Improve patient outcomes in urology
|
| gptkbp:partnership |
Collaboration with various research institutions
|
| gptkbp:product |
gptkb:Uro_Gen
|
| gptkbp:research_areas |
Drug delivery systems
|
| gptkbp:technology |
Nanoparticle technology
|
| gptkbp:website |
www.tarisbiomedical.com
|
| gptkbp:bfsParent |
gptkb:Johnson_&_Johnson
|
| gptkbp:bfsLayer |
4
|